Mirum Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $618.1M+83.5% YoYTTM through 30 Jun 2026
Net Income -$860.2MTTM through 30 Jun 2026
Free Cash Flow -$228.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -130.7% |
| Operating Margin | -134.9% |
| Net Margin | -139.2% |
Returns
-10.4%ROE
-2.8%ROA
Balance Sheet Health
Debt / Equity1.37x
Current Ratio2.67x
Net Debt$13.1M
Cash & Equivalents$330.7M
Quality Metrics
Altman Z-Score-0.24
Piotroski F-Score3 / 9
FCF Margin-37.0%
Rule of 40-24.3
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $521.3M
Diluted EPS-$14.08TTMFY2025: $-0.47
Dividend
No dividend
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| LIVMARLI | $360M | +69.0% | |
| Bile Acid Medicines | $161.3M | +31.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.